Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications

<div>New drug formulations containing DCA. (a) Schematic representation of Os-DCA and Ru-DCA complexes [<a href="/journals/omcl/2019/8201079/#B81">81</a>]. (b) Doxorubicin (DOX)-DCA complex [<a href="/journals/omcl/2019/8201079/#B83">83</a>]. (c) Dual action Pt prodrugs of kiteplatin and DCA [<a href="/journals/omcl/2019/8201079/#B84">84</a>]. (d) Examples of triple action Pt(<sub>IV</sub>) derivatives of cisplatin containing DCA (red), derivatives of cisplatin (black), and COX inhibitors (green) [<a href="/journals/omcl/2019/8201079/#B85">85</a>]. (e) Chemical structure of DPB containing DCA (red), biotin (blue), and Platinum (Pt) complex (black) [<a href="/journals/omcl/2019/8201079/#B86">86</a>].</div>

Oxidative Medicine and Cellular Longevity

fig2

Figure 2

Figure 2: Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications 